<DOC>
	<DOCNO>NCT00857311</DOCNO>
	<brief_summary>A Study ass general safety tolerability administration 3-dose prime/boost regimen MRKAd5 HIV-1 gag vaccine ( V520 ) subject chronic hepatitis C virus infection .</brief_summary>
	<brief_title>MRKAd5 HIV-1 Gag Vaccine ( V520 ) Subjects With Chronic Hepatitis C ( V520-022 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject reproductive potential agrees use acceptable method birth control week 52 study Subject weigh less 110 lb . Subject receive treatment hepatitis C virus infection 3 month enrollment study anticipate begin treatment 1 year enrollment Subject history anaphylaxis allergy vaccine component Subject history anaphylaxis allergy Tetanus Diphtheria Toxoids Adsorbed ( Td ) Subject clinical sign suggestive cirrhosis Subject liver biopsy show bridge fibrosis cirrhosis Subject HBsAg positive Subject know chronic liver disease Subject evidence hepatocellular carcinoma liver biopsy Subject liver transplant anticipate liver transplant within 1 year enrollment Subject vaccinate live virus vaccine past 30 day Subject vaccinate inactive virus vaccine past 14 day Female subject pregnant breastfeeding , Male subject plan impregnate Subject active drug alcohol abuse Subject high risk HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>